Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Ikuro MatsubaTakehiro KawataKotaro IemitsuTaro AsakuraHikaru AmemiyaMasashi IshikawaSyogo ItoMizuki KaneshiroAkira KanamoriAkira KubotaKazuaki ShinodaMasahiko TakaiTetsuo TakumaMasahiro TakihataHiroshi TakedaKeiji TanakaYoko MatsuzawaHideo MachimuraFuyuki MinagawaNobuaki MinamiAtsuko MokuboMasaaki MiyakawaYasuo TerauchiYasushi TanakaPublished in: Journal of diabetes investigation (2020)
Ipragliflozin lowers eGFR and corrects hyperfiltration in patients with high eGFR (eGFR ≥60). In patients with low eGFR (eGFR ≥30 to <60), ipragliflozin has the possibility of increasing eGFR and exerting a renoprotective effect.